Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$117.61 USD

117.61
1,212,963

+3.12 (2.73%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $117.69 +0.08 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Why Illumina (ILMN) Could Beat Earnings Estimates Again

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Wall Street Analysts Think Illumina (ILMN) Could Surge 27.02%: Read This Before Placing a Bet

The consensus price target hints at a 27% upside potential for Illumina (ILMN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Illumina (ILMN) Upgraded to Buy: Here's Why

Illumina (ILMN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Illumina (ILMN) Buys Fluent, Grows in Single Cell Research

By integrating Fluent's unique technology with Illumina's (ILMN) sequencing and informatics solutions, researchers are likely to gain access to a comprehensive solution for single-cell multiomic analysis.

Illumina (ILMN) Rises on Conclusion of GRAIL Divestment

With the divestment now over, we expect Illumina (ILMN) to soar again on the assumption that the company will start to focus on its legacy businesses.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Illumina (ILMN) Advances in NGS With DRAGEN v4.3 Launch

One of the standout features of Illumina's (ILMN) DRAGEN v4.3 is its machine-learning mosaic model.

The Zacks Analyst Blog Highlights Union Pacific, Freeport-McMoRan, Block, Xcel and Illumina

Union Pacific, Freeport-McMoRan, Block, Xcel and Illumina are included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Union Pacific, Freeport-McMoRan & Block

Today's Research Daily features new research reports on 16 major stocks, including Union Pacific Corporation (UNP), Freeport-McMoRan Inc. (FCX) and Block, Inc. (SQ).

Illumina (ILMN) Q1 Earnings Beat, Adjusted Operating Loss Widens

Illumina (ILMN) surpasses expectations in the first quarter in a challenging global macroeconomic environment.

Illumina (ILMN) Reports Q1 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Urmimala Biswas headshot

Will These 5 MedTech Stocks Beat Forecasts This Earnings Season?

Here is a sneak peek into how the five MedTech stocks, HOLX, ZBH, ILMN, TFX and BRKR, are expected to fare in their quarterly results slated to be released tomorrow.

Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out for

AbCellera Biologics (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gear Up for Illumina (ILMN) Q1 Earnings: Wall Street Estimates for Key Metrics

Evaluate the expected performance of Illumina (ILMN) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Illumina (ILMN) Expected to Beat Earnings Estimates: Should You Buy?

Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Can Illumina (ILMN) Keep the Earnings Surprise Streak Alive?

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Exact Sciences (EXAS) Up 4.2% Since Last Earnings Report: Can It Continue?

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?

Smart Beta ETF report for RSPH

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Smart Beta ETF report for PBE